A review highlights new and emerging treatments for generalized pustular psoriasis, with a focus on IL-36 inhibitors.

Generalized pustular psoriasis (GPP) is a rare, severe form of pustular psoriasis that affects large areas of the body and can cause life threatening symptoms like high fever and rapid pulse. The ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

Please provide your email address to receive an email when new articles are posted on . Spevigo (spesolimab) reduced the risk for generalized pustular psoriasis flares by 84% over 48 weeks. Spevigo’s ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

Pustular psoriasis is characterized by clearly defined, raised pus-filled blisters, that cover large swatches of skin and is sometimes accompanied by fever, chills and severe itching. This form of ...

A team from Nagoya University in Japan has identified previously unidentified gene variants that are associated with the development of generalized pustular psoriasis (GPP). The team's findings, ...

The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly more healthcare visits and costs than patients with plaque psoriasis alone. Researchers ...

Mark G. Lebwohl, MD, explains what causes generalized pustular psoriasis (GPP) and the potential triggers for GPP episodes. Ryan Haumschild, PharmD, MS, MBA: Dr Lebwohl, you gave us a great overview.